AMOEBA overview

Chassieu (France), 14 April 2025 – 8.45 a.m. - Amoéba (FR0011051598 - ALMIB ) , an industrial green tech company specialized in the development of natural microbiological solutions based on the patented exploitation of amoebae , announces that the research department of the Belgian financial services group KBC Securities has initiated the coverage of its stock. KBC Securities has initiated coverage of the stock as part of a study entitled “ An amoebalicious adventure from fungus fighters to...

Press release Chassieu (France), 1 st April 2025 – 6 pm - Amoéba (FR0011051598 - ALMIB) , industrial greentech specialized in the development of natural microbiological solutions based on the patented use of amoebae, is proud to announce the signing of a Memorandum of Understanding (MoU) with Metron Technology, a subsidiary of the Chinese Oriental Beauty Valley group (OBV group), with a view to signing an agreement for the registration of its own natural cosmetic ingredient in China, and for...

Press release Two decisive milestones in 2024 in the field of biocontrol : the signing of a Memorandum of Understanding (MoU) with Koppert, world leader in biocontrol, and the receipt of the EFSA's positive and definitive conclusions on its biocontrol active substance; Major advances in the field of cosmetics with the excellent results of the clinical study, the inclusion of the ingredient on the INCI list (International Nomenclature for Cosmetic Ingredients) and Cosmos certification; 2024...

Press release Chassieu (France), 20 March 2025 - 6pm - Amoéba (FR0011051598 - ALMIB) , an industrial greentech specialized in the development of natural microbiological solutions based on the patented use of amoebae, announces its participation for the 2 nd consecutive year in the European SAGROPIA project , which aims to advance crop protection using pesticides of natural origin. Alongside leading players in their fields of expertise, Amoéba is proud to be the only French company to take part...

Press release Chassieu (France), 10 March 2025 - 6 pm - Amoéba (FR0011051598 - ALMIB ), an industrial greentech specialising in the development of natural microbiological solutions based on the patented use of amoebae, announces the extension of production capacity at its Chassieu site (Greater Lyon, France), in line with its roadmap, at a time when commercial negotiations for its "AXPERA" range of biocontrol products are moving forward. Following the signing of a memorandum of understanding...

Press release Chassieu (France), 23 January 2025 – 6.00 pm - Amoéba (FR0011051598 - ALMIB), an industrial greentech specialising in the development of natural microbiological solutions based on the patented use of amoebae, announces that Euroland Corporate has initiated the coverage of its stock. Euroland Corporate has begun monitoring the stock as part of a study entitled " On the road to commercialisation ", with a Buy recommendation and a target price of €2.40 per share (representing...

Press release Chassieu (France), 15 January 2025 – 5.45 pm - Amoéba (FR0011051598 - ALMIB), an industrial greentech specialising in the development of natural microbiological solutions based on the patented use of amoebae, announces that the European Food Safety Authority (EFSA) has published the final assessment report on Amoéba's biocontrol active substance [1] . As a reminder, Amoéba received on 13 December 2024 [2] the positive and definitive conclusions of the EFSA, which validated the...

Asieris and CDC Sign Investigational Product Supply Agreement for APL-1202 in Free-Living Amoeba Infections Treatment under Expanded Access Investigational New Drug Program PR Newswire SHANGHAI, Jan. 6, 2025 SHANGHAI , Jan. 6, 2025 /PRNewswire/ -- Asieris Pharmaceuticals (Stock Code: 688176.SH), a leading global biopharmaceutical company dedicated to advancing innovative therapies for genitourinary tumors and women's health with significant unmet medical needs, announced the signing of an...